Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:ARVN NASDAQ:KRTX NASDAQ:MOR NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.05+2.0%$28.17$25.17▼$36.45$4.46B0.531.79 million shs467,776 shsARVNArvinas$7.61-1.7%$7.51$5.90▼$29.61$559.81M2.382.09 million shs605,204 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$26.96+0.4%$24.38$13.42▼$27.64$1.21B0.42787,151 shs266,398 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.67%-6.78%-8.71%-10.92%-4.12%ARVNArvinas0.00%-2.52%+9.17%+3.48%-69.10%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-0.96%+0.45%+8.39%+10.13%+104.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.05+2.0%$28.17$25.17▼$36.45$4.46B0.531.79 million shs467,776 shsARVNArvinas$7.61-1.7%$7.51$5.90▼$29.61$559.81M2.382.09 million shs605,204 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$26.96+0.4%$24.38$13.42▼$27.64$1.21B0.42787,151 shs266,398 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.67%-6.78%-8.71%-10.92%-4.12%ARVNArvinas0.00%-2.52%+9.17%+3.48%-69.10%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-0.96%+0.45%+8.39%+10.13%+104.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.92Moderate Buy$41.8554.73% UpsideARVNArvinas 2.55Moderate Buy$19.76159.80% UpsideKRTXKaruna Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/APCRXPacira BioSciences 2.71Moderate Buy$30.8314.38% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, KRTX, PCRX, ALKS, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.008/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.007/30/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$40.00 ➝ $42.007/29/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B2.87$2.66 per share10.17$9.05 per share2.99ARVNArvinas$372.80M1.50N/AN/A$8.17 per share0.93KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PCRXPacira BioSciences$705.85M1.72$4.29 per share6.28$16.86 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0812.9919.741.5223.15%24.86%17.14%10/23/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)KRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APCRXPacira BioSciences-$99.56M-$2.78N/A10.49N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest ARVN, KRTX, PCRX, ALKS, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85ARVNArvinasN/A5.645.64KRTXKaruna TherapeuticsN/A19.3119.31MORMorphoSys4.981.381.38PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ARVNArvinas95.19%KRTXKaruna TherapeuticsN/AMORMorphoSys18.38%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%ARVNArvinas4.73%KRTXKaruna Therapeutics13.20%MORMorphoSys0.05%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableARVNArvinas42073.42 million69.95 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableARVN, KRTX, PCRX, ALKS, and MOR HeadlinesRecent News About These Companies51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLPSeptember 12, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 9, 2025 | marketbeat.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comBridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $32.51 Million Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comRafferty Asset Management LLC Takes $251,000 Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comPDT Partners LLC Has $5.14 Million Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 3, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLCSeptember 1, 2025 | marketbeat.com9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLCSeptember 1, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Holdings Lifted by Walleye Capital LLCAugust 30, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Wellington Management Group LLPAugust 29, 2025 | marketbeat.comQuantbot Technologies LP Purchases 24,102 Shares of Pacira BioSciences, Inc. $PCRXAugust 28, 2025 | marketbeat.comMartingale Asset Management L P Takes Position in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Holdings in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Pacira BioSciences, Inc. $PCRXAugust 26, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Invesco Ltd.August 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pacira BioSciences, Inc. $PCRXAugust 24, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Uranium Energy Stock Has Momentum—and More Upside AheadBy Gabriel Osorio-Mazilli | September 16, 2025ARVN, KRTX, PCRX, ALKS, and MOR Company DescriptionsAlkermes NASDAQ:ALKS$27.04 +0.53 (+1.98%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Arvinas NASDAQ:ARVN$7.60 -0.14 (-1.74%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/15/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Pacira BioSciences NASDAQ:PCRX$26.95 +0.09 (+0.34%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
